Skip to content
Open access

Notoginsenoside R1 attenuates ischemic stroke via CKLF1-dependent suppression of neuronal metabolic reprogramming

Oct 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 46 references
Medicine

TL;DR

NGR1 alleviates ischemic neuronal injury, at least in part, by interfering with CKLF1/CCR5-associated signaling, thereby attenuating pathological metabolic reprogramming, neuroinflammation, and apoptosis.

Abstract

Background Ischemic stroke, a leading cause of global mortality and disability, results from cerebral blood flow disruption, driving metabolic and neuronal dysfunction. Current therapies-thrombolysis, thrombectomy, and neuroprotectants-are constrained by narrow time windows and hemorrhagic risks. Notoginsenoside R1 (NGR1), a bioactive saponin from Panax notoginseng, exhibits multimodal neuroprotection, yet its mechanistic interplay with metabolic pathways remains unclear. Objective We investigated NGR1’s neuroprotective efficacy in ischemic stroke, focusing on its modulation of the CKLF1/CCR5 axis and metabolic reprogramming. Methods This study employs a multi-tiered approach integrating in vitro experiments, in vivo animal research, computationally validated target simulations, and gene knockout techniques to systematically elucidate NGR1’s regulatory role in key indicators during ischemic stroke treatment. Molecular docking and kinetic modelling first predicted NGR1-CKLF1 binding, subsequently validated via Cellular Thermal Shift Assay (CETSA) and Drug Affinity Responsive Target Stability (DARTS) experiments. In vitro experiments employed a PC12 cell oxygen-glucose deprivation (OGD) model to evaluate NGR1’s neuroprotective effects. CCK-8 assays, live-dead Cell staining, metabolic assay kits, TUNEL and JC-1 staining, Western blot (WB) analysis, and immunofluorescence (IF) co-localization revealed in vitro metabolic reprogramming mechanisms. In vivo experiments employed a permanent middle cerebral artery occlusion (pMCAO) model to mimic human ischemic pathophysiology. Neuronal metabolic reprogramming mechanisms following NGR1 treatment were elucidated via TTC staining, neurobehavioral testing, Nissl staining, Enzyme-linked immunosorbent assay (ELISA) assays, immunohistochemical (IHC), WB, IF, and Co-immunoprecipitation (Co-IP). Pharmacodynamic evaluation in the CKLF1−/− rat middle cerebral artery occlusion model, employing ELISA assays and WB analysis, confirmed NGR1’s specificity towards CKLF1. Results Docking and MD predicted a stable NGR1–CKLF1 interaction; CETSA/DARTS supported a direct physical interaction, but binding-affinity constants were not determined. In vitro, NGR1 mitigated OGD-induced metabolic dysregulation, inhibited apoptosis, and enhanced neuronal survival. In vivo experiments demonstrated that NGR1 reduced infarct volume, improved neurological behavior scores, mitigated Nissl body damage, and alleviated inflammatory responses. Mechanistically, NGR1 inhibits downstream AMPK/mTOR/HIF-1α-driven neuronal metabolic reprogramming characterized by glycolytic activation by disrupting CKLF1-CCR5 binding. CKLF1 knockout abolished NGR1’s therapeutic effects and its role in neuronal metabolic reprogramming, confirming CKLF1 dependency. Conclusion NGR1 alleviates ischemic neuronal injury, at least in part, by interfering with CKLF1/CCR5-associated signaling, thereby attenuating pathological metabolic reprogramming, neuroinflammation, and apoptosis. Clinical relevance requires further validation.

Read PDF

Similar papers

Oct 2026

Endothelial Malat1 promotes post-stroke angiogenesis and neurovascular recovery via the Tek axis.

It is demonstrated that the long non-coding RNA Malat1 acts as a critical endothelial regulator of angiogenesis and neurological restoration and establishes the Malat1-Tek axis as a novel signaling pathway essential for driving post-ischemic cerebrovascular remodeling and long-term functional recovery.

Tian-Qing Xiong, Meng-Qi Zhang, Ping Sun et al. · 0 citations
Sep 2026

N1-methylnicotinamide Mediates Multi-Target Cognitive Deficit Relief via AMPK-Lysosome Axis Regulation.

INTRODUCTION/OBJECTIVE Alzheimer's Disease (AD) progresses via interconnected Aβ aggregation, tau hyperphosphorylation, neuroinflammation, and lysosomal failure, while current single-target drugs only relieve cognitive symptoms without halting pathogenesis. Gut microbiota-derived N1-methylnicotinamide (MNAM) is associa...

Xiang-Jie Qiu, Qi-Lei Zhang, Yu-Ting Meng et al. · 0 citations
Oct 2026

Zedoarondiol Targets GYG1 to Alleviate Myocardial Ischemia-Reperfusion Injury

Myocardial ischemia/reperfusion injury (MIRI) remains a major clinical problem, marked by acute bioenergetic dysfunction and Ca2+ overload that contribute to cardiomyocyte death after ischemia. In this study, we showed that Zedoarondiol (Zed), a natural compound, significantly attenuated myocardial injury and cardiom...

Nan-Nan Wang, Hui Zhao, Jia-Zheng Li et al. · 0 citations
Review Open access Sep 2026

Catechins in stroke: multi-target mechanisms, preclinical evidence, and translational challenges

Catechins represent promising candidate drugs for stroke due to their multiple neuroprotective potentials, but most preclinical evidence arises from pretreatment paradigms, which are confounded by heterogeneity in dosage, age, and experimental models.

Yue Zhang, Shuang-Cui Wang, Qing-Qiang Yuan · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.